Compare AEIS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEIS | PRAX |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 9.6B |
| IPO Year | 1996 | 2020 |
| Metric | AEIS | PRAX |
|---|---|---|
| Price | $385.96 | $331.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | $307.73 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 498.5K | 340.4K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ 168.53 | N/A |
| EPS | ★ 3.84 | N/A |
| Revenue | ★ $453,095,000.00 | N/A |
| Revenue This Year | $22.53 | N/A |
| Revenue Next Year | $13.38 | $7,758.26 |
| P/E Ratio | $100.89 | ★ N/A |
| Revenue Growth | ★ 38.39 | N/A |
| 52 Week Low | $92.83 | $34.89 |
| 52 Week High | $397.44 | $354.87 |
| Indicator | AEIS | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 52.86 |
| Support Level | $292.26 | $282.49 |
| Resistance Level | N/A | $353.83 |
| Average True Range (ATR) | 13.92 | 17.80 |
| MACD | -0.03 | 0.80 |
| Stochastic Oscillator | 66.64 | 47.50 |
Advanced Energy Industries Inc provides precision power conversion, measurement, and control solutions. The company designs, manufactures, sells, and services power electronics conversion products that transform raw electrical power into controllable, usable power for complex equipment. It operates in one reporting segment, Power Electronics Conversion Products, serving the Semiconductor Equipment, Data Center Computing, Industrial and Medical, and Telecom and Networking markets. Its products include Plasma Power Products, AC-DC Power Supply Units, DC-DC Converters, High Voltage solutions, SCR Power Controllers, and Sense and Measurement solutions. The company operates in the United States, Asia, Europe, and other regions.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.